Fischer M-O, Parienti J-J, Daurel C, Debruyne D, Verdon R, Gérard J-L, Hanouz J-L, Fellahi J-L
Pôle anesthésie-réanimation-Samu-Smur-coordination hospitalière-hémovigilance, CHU de Caen, France.
Ann Fr Anesth Reanim. 2012 Jan;31(1):e1-5. doi: 10.1016/j.annfar.2011.08.021. Epub 2011 Dec 6.
Septic shock remains a major cause of death in intensive care units (ICU) and an inappropriate antibiotic regimen worsens the prognosis. The aim of the study was to assess the impact of an information campaign on modalities of prescription of aminoglycosides in septic shock.
A prospective observational study.
Consecutive septic shock patients admitted to the surgical ICU over a 2-year period were included. An information campaign allowed to differentiate between a pre- (P1) and a post- (P2) interventional period. The campaign clarified the rules and requirements for pharmacological monitoring of aminoglycosides. The main objective was to increase the rate of prescription of peak serum aminoglycoside following the first intravenous injection.
One hundred and forty-eight patients (P1=76 and P2=72) were finally included into the study. Similar clinical characteristics were observed during both periods. The rate of prescription of peak serum aminoglycoside following the first injection was performed in 49% (P1) versus 65% (P2), P=0.09. The length of stay in ICU was 16 days [extremes: 1-74] (P1) versus 17 days [extremes: 1-133] (P2) (P=0.84). Inhospital mortality was 28% (P1) versus 26% (P2), P=0.86.
An information campaign describing the modalities of prescription of aminoglycosides in septic shock failed to improve medical practices and patient outcomes. A mobile team of antibiotics could be useful in daily practice.
感染性休克仍是重症监护病房(ICU)患者死亡的主要原因之一,不恰当的抗生素治疗方案会使预后恶化。本研究旨在评估一项信息宣传活动对感染性休克患者氨基糖苷类药物处方方式的影响。
一项前瞻性观察性研究。
纳入连续2年入住外科ICU的感染性休克患者。开展一项信息宣传活动,区分干预前(P1)和干预后(P2)两个阶段。该活动阐明了氨基糖苷类药物药理监测的规则和要求。主要目标是提高首次静脉注射后血清氨基糖苷类药物峰值的处方率。
最终148例患者(P1 = 76例,P2 = 72例)纳入研究。两个阶段观察到相似的临床特征。首次注射后血清氨基糖苷类药物峰值的处方率在P1阶段为49%,P2阶段为65%,P = 0.09。ICU住院时间P1阶段为16天[范围:1 - 74天],P2阶段为17天[范围:1 - 133天](P = 0.84)。住院死亡率P1阶段为28%,P2阶段为26%,P = 0.86。
一项描述感染性休克患者氨基糖苷类药物处方方式的信息宣传活动未能改善医疗实践和患者预后。抗生素流动团队在日常实践中可能会有所帮助。